Discontinued — last reported Q4 '24
COVID-19 — Sales to Customers
Johnson & Johnson COVID-19 — Sales to Customers decreased by 100.0% to $0.00 in Q4 2024 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $44.00M to $0.00. Over 3 years (FY 2021 to FY 2024), COVID-19 — Sales to Customers shows a downward trend with a -56.4% CAGR.
Analysis
How to read this metric
An increase indicates higher demand or successful market penetration of pandemic-related products, while a decrease suggests a decline in pandemic-driven market needs or product lifecycle maturity.
Detailed definition
This metric represents the total revenue generated from the sale of COVID-19 related products, such as vaccines or thera...
Peer comparison
Comparable to pandemic-related revenue segments reported by other pharmaceutical and biotechnology firms, though specific product portfolios vary significantly.
jnj_segment_covid_19_sales_to_customersHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $164.00M | $502.00M | $1.62B | $457.00M | $544.00M | $489.00M | $689.00M | $747.00M | $285.00M | $41.00M | $44.00M | $25.00M | $172.00M | $1.00M | $0.00 |
| QoQ Change | — | +206.1% | +222.5% | -71.8% | +19.0% | -10.1% | +40.9% | +8.4% | -61.8% | -85.6% | +7.3% | -43.2% | +588.0% | -99.4% | -100.0% |
| YoY Change | — | — | — | — | +231.7% | -2.6% | -57.4% | +63.5% | -47.6% | -91.6% | -93.6% | -96.7% | -39.6% | -97.6% | -100.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's covid-19 — sales to customers?
- Johnson & Johnson (JNJ) reported covid-19 — sales to customers of $0.00 in Q4 2024.
- How has Johnson & Johnson's covid-19 — sales to customers changed year-over-year?
- Johnson & Johnson's covid-19 — sales to customers decreased by 100.0% year-over-year, from $44.00M to $0.00.
- What is the long-term trend for Johnson & Johnson's covid-19 — sales to customers?
- Over 3 years (2021 to 2024), Johnson & Johnson's covid-19 — sales to customers has grown at a -56.4% compound annual growth rate (CAGR), from $2.39B to $198.00M.
- What does covid-19 — sales to customers mean?
- Total revenue earned from the sale of COVID-19 related medical products.